Viewing Study NCT00002635



Ignite Creation Date: 2024-05-05 @ 11:22 AM
Last Modification Date: 2024-10-26 @ 9:03 AM
Study NCT ID: NCT00002635
Status: COMPLETED
Last Update Posted: 2013-07-26
First Post: 1999-11-01

Brief Title: Aminocamptothecin in Treating Patients With T-cell Lymphoma
Sponsor: Yale University
Organization: Yale University

Study Overview

Official Title: PHASE II TRIAL OF 9-AMINOCAMPTOTHECIN IN ADVANCED CUTANEOUS T CELL LYMPHOMA
Status: COMPLETED
Status Verified Date: 2001-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die

PURPOSE Phase II trial to study the effectiveness of aminocamptothecin in treating patients with advanced cutaneous T-cell lymphoma
Detailed Description: OBJECTIVES I Assess the antitumor activity of aminocamptothecin 9-AC administered by 72-hour infusion in patients with advanced cutaneous T-cell lymphoma II Assess the toxic effects of 9-AC administered on this schedule

OUTLINE Single-Agent Chemotherapy Aminocamptothecin 9-AC NSC-603071

PROJECTED ACCRUAL A total of 30 patients will be accrued if no more than 1 response is seen in the first 15 patients the study will close Probable duration of study is 18 months

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
NCI-T94-0189D None None None
YALE-HIC-7862 None None None